Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Ferte

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Plos One|March 19, 2011
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trialsCharles Ferte, Jean-Charles Soria, Nicolas Penel
Bulletin Du Cancer|October 3, 2008
[Merkel cell carcinoma: current diagnosis and treatment]Laurent Mortier, Xavier Mirabel, Charles Ferte, et al.
Plos One|January 10, 2013
Predictive value of clinical judgment of tumour progression in phase II trialsNuria Kotecki, Nicolas Penel, Antoine Adenis, et al.
Investigational New Drugs|January 10, 2009
"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agentsNicolas Penel, Nicolas Isambert, Pierre Leblond, et al.
The Laryngoscope|November 27, 2016
Outcomes following laryngectomy refusal after insufficient response to induction chemotherapyPhilippe Gorphe, Margarida Matias, Pierre Blanchard, et al.
Clinical Lung Cancer|October 8, 2009
Pemetrexed-induced pneumonitis: a case reportYohann Loriot, Charles Ferte, Carlos Gomez-Roca, et al.
Plos One|August 4, 2009
Development and validation of a bedside score to predict early death in cancer of unknown primary patientsNicolas Penel, Sylvie Negrier, Isabelle Ray-Coquard, et al.
Anticancer Research|December 7, 2016
Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell CarcinomaPhilippe Gorphe, Margarida Matias, Caroline Even, et al.
Immunotherapy|September 12, 2024
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumorsBen Tran, Mark Voskoboynik, Johanna Bendell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Plos One|March 19, 2011
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trialsCharles Ferte, Jean-Charles Soria, Nicolas Penel
Bulletin Du Cancer|October 3, 2008
[Merkel cell carcinoma: current diagnosis and treatment]Laurent Mortier, Xavier Mirabel, Charles Ferte, et al.
Plos One|January 10, 2013
Predictive value of clinical judgment of tumour progression in phase II trialsNuria Kotecki, Nicolas Penel, Antoine Adenis, et al.
Investigational New Drugs|January 10, 2009
"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agentsNicolas Penel, Nicolas Isambert, Pierre Leblond, et al.
The Laryngoscope|November 27, 2016
Outcomes following laryngectomy refusal after insufficient response to induction chemotherapyPhilippe Gorphe, Margarida Matias, Pierre Blanchard, et al.
Clinical Lung Cancer|October 8, 2009
Pemetrexed-induced pneumonitis: a case reportYohann Loriot, Charles Ferte, Carlos Gomez-Roca, et al.
Plos One|August 4, 2009
Development and validation of a bedside score to predict early death in cancer of unknown primary patientsNicolas Penel, Sylvie Negrier, Isabelle Ray-Coquard, et al.
Anticancer Research|December 7, 2016
Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell CarcinomaPhilippe Gorphe, Margarida Matias, Caroline Even, et al.
Immunotherapy|September 12, 2024
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumorsBen Tran, Mark Voskoboynik, Johanna Bendell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
Pageof 2